Page last updated: 2024-11-05

c 137

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

C 137: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14169
CHEMBL ID124006
SCHEMBL ID4725486
MeSH IDM0083612

Synonyms (43)

Synonym
9-(3'-dimethylaminopropylamino)acridine
brn 0485893
9-((3-dimethylaminopropyl)amino)acridine
ccris 1974
c 137
1,3-propanediamine, n'-9-acridinyl-n,n-dimethyl-
n'-9-acridinyl-n,n-dimethyl-1,3-propanediamine
acridine, 9-(3-(dimethylamino)propylamino)-
n'-acridin-9-yl-n,n-dimethylpropane-1,3-diamine
smr000558991
MLS001198528 ,
TCMDC-124266 ,
n-acridin-9-yl-n',n'-dimethylpropane-1,3-diamine
mmv000448
gnf-pf-2110 ,
sj000044378
CHEMBL124006
AKOS001678876
NCGC00245884-01
unii-c9lk54b52h
c9lk54b52h ,
13365-37-2
HMS2884I12
n'-(acridin-9-yl)-n,n-dimethylpropane-1,3-diamine
STK589099
SCHEMBL4725486
bdbm80560
n-acridin-9-yl-n'',n''-dimethyl-propane-1,3-diamine
3-(acridin-9-ylamino)propyl-dimethyl-amine
cid_14169
n-(9-acridinyl)-n'',n''-dimethylpropane-1,3-diamine
n-acridin-9-yl-n'',n''-dimethylpropane-1,3-diamine
9-[3-(dimethylamino)propylamino]acridine
DTXSID40158291
sr-01000088074
SR-01000088074-1
n1-(9-acridinyl)-n3,n3-dimethyl-1,3-propanediamine
dimethylaminopropylamino)acridine, 9-(3'-
c-137
1,3-propanediamine, n3-9-acridinyl-n1,n1-dimethyl-
nsc766436
nsc-766436
mfcd01084589

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Some N-oxide derivatives of DNA intercalators are bioreductive prodrugs that are selectively toxic under hypoxic conditions."( Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.
Denny, WA; Hicks, KO; Pullen, SM; Siim, BG; van Zijl, PL; Wilson, WR, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency9.46620.003245.467312,589.2998AID2517
Chain A, Ferritin light chainEquus caballus (horse)Potency14.12545.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency3.54810.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588456
WRNHomo sapiens (human)Potency22.38720.168331.2583100.0000AID651768
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency2.75110.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency3.98110.00527.809829.0929AID588855
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency14.12540.28189.721235.4813AID2326
67.9K proteinVaccinia virusPotency7.99600.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency28.18380.01268.156944.6684AID2101
P53Homo sapiens (human)Potency44.66840.07319.685831.6228AID504706
IDH1Homo sapiens (human)Potency4.10950.005210.865235.4813AID686970
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.98110.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency50.11870.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency76.00645.804836.130665.1308AID540253; AID540263
DNA polymerase betaHomo sapiens (human)Potency2.23870.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency9.85610.133725.412989.1251AID588795; AID720498
ras-related protein Rab-9AHomo sapiens (human)Potency1.41250.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency76.00645.804836.130665.1308AID540253; AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency89.12510.010323.856763.0957AID2662
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency39.81075.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency9.76690.050127.073689.1251AID588590; AID720496
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency1.45810.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency17.29260.031622.3146100.0000AID588579; AID720501
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
Glycoprotein hormones alpha chainHomo sapiens (human)Potency1.58494.46688.344810.0000AID624291
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)58.00000.270026.3638100.0000AID504723
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)18.00001.480014.526761.2000AID504724
Glucose transporterLeishmania mexicanaIC50 (µMol)2.24800.08102.30676.7450AID1207598
Hexose transporter 1 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.82900.09002.22205.8850AID1207597
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)1.55800.00492.99549.9920AID1207599
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7IC50 (µMol)1.00000.00210.00760.0130AID1159502
Lysine--tRNA ligase Plasmodium falciparum 3D7IC50 (µMol)2.50000.12000.12000.1200AID1159505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alternatively spliced Trp4Mus musculus (house mouse)EC50 (µMol)1.33330.00033.337010.5907AID434942
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7Homo sapiens (human)AC500.87900.039815.002550.0000AID743267
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC500.81400.814019.311978.9500AID651657
DNA repair protein RAD52 homolog isoform aHomo sapiens (human)AC500.27100.150012.066235.2100AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID229742Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-4) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID229743Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-5) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449707ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye2010Nature, May-20, Volume: 465, Issue:7296
Chemical genetics of Plasmodium falciparum.
AID449708ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye2010Nature, May-20, Volume: 465, Issue:7296
Chemical genetics of Plasmodium falciparum.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID45745Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID602118NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID229741Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (EM-9) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (16.67)18.7374
1990's1 (5.56)18.2507
2000's6 (33.33)29.6817
2010's7 (38.89)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.68 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index125.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]